Search

Your search keyword '"Bachmeier, Christina A"' showing total 26 results

Search Constraints

Start Over You searched for: Author "Bachmeier, Christina A" Remove constraint Author: "Bachmeier, Christina A" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
26 results on '"Bachmeier, Christina A"'

Search Results

1. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

6. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis

8. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma

9. Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

11. Impact of Sarcopenia and Subsequent Muscle Loss on Post-CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma

13. Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma

14. Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia

15. A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

16. 245 - Fludarabine Exposure Impact on Safety and Efficacy of Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM)

17. 238 - Outcomes of CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma in Patients with Reduced Renal Function Including Dialysis

18. Primary Progression on Frontline Therapy for Diffuse Large B-Cell Lymphoma Is Associated with a Poor Outcome Despite Subsequent CD19 Targeted CAR T-Cell Therapy

19. Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel

20. Identification of Early Predictive Markers of Toxicity and Efficacy in Patients with DLBCL Treated with Axicabtagene Ciloleucel

21. Incidence and Management of Effusions during CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Receptor Therapy in B-Cell Lymphoma: A Single Institution Experience

22. Hypofibrinogenemia in Patients Receiving CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Large B Cell Lymphoma: A Single Institution Experience

23. Incidence and Management of Venous Thrombo-Embolism (VTE) Associated with CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Single Institution Experience

Catalog

Books, media, physical & digital resources